Sign In
Buy SLNO
$53.01
+0 (+0%)
At Close: Jun 23, 2026
TD Asset Management Inc Has $8.36 Million Stock Holdings in Soleno Therapeutics, Inc. $SLNO
04:42am, Monday, 20'th Oct 2025
TD Asset Management Inc boosted its stake in shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 34.9% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund o
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advis
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeuti
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
08:00pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
02:00pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advis
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeuti
Soleno: Blockbuster Launch In Progress
08:45am, Saturday, 11'th Oct 2025
Soleno Therapeutics is reassessed after a 24% drop post-VYKAT XR approval enthusiasm. SLNO now faces the critical 'danger zone' between FDA approval and successful commercialization of VYKAT XR for Pr
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeuti
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman
01:47pm, Thursday, 09'th Oct 2025
SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report
Scorpion Capital alleged Soleno's sole product, Vykat XR, was overpriced and unsafe for children, causing shares to drop 7.4% to $71.63 on August 15, 2025.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
05:45pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutic
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
03:00pm, Sunday, 05'th Oct 2025
NEW YORK , Oct. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics,
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
10:00am, Friday, 03'rd Oct 2025
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advi
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutic
